Solifenacin + Mirabegron

ApprovedSmall molecule

Solifenacin + Mirabegron is one of 23 small molecule programs targeting Urinary incontinence. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Urinary IncontinenceActive, not recruiting

Urinary IncontinenceApproved

Active, not recruiting

Competition

Competitive Landscape

40 competitors in Urinary Incontinence

#DrugCompanyPhaseTrials

Vesicare

Astellas

Approved

8 2

Myrbetriq

Astellas

Approved

2 3

Enablex

AbbVie

Approved

—4

Cymbalta

Alnylam Pharmaceuticals

Toviaz

Xylocaine

Alka-Seltzer

Isopto Carpine

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 3

8 10

Oxytrol

WWim Janssens

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Post-ApprovalRecruiting

Urinary Incontinence

NCT06465576

Clinical

Trials by Indication[1]

Urinary incontinence1 trial

Strategy for Withdrawal of Pharmacological Treatment for Urinary Incontinence in Children (StayDry)

Recruiting·UUniversity of Aarhus·Phase 4·NCT06465576·216 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Solifenacin + Mirabegron. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Solifenacin + Mirabegron compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Solifenacin + Mirabegron. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Aarhus company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUniversity of Aarhus

Solifenacin + Mirabegron

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Urinary incontinence1 trial

References

Drug Info

Quick Facts

Related News